PPA
CYCN icon

Parametric Portfolio Associates’s Cyclerion Therapeutics CYCN Stock Holding History

Parametric Portfolio Associates’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-630
Closed -$49K – 3617
2021
Q2 		$49K Sell
630
-683
-52% -$42.8K ﹤0.01% 3536
2021
Q1 		$73K Buy
1,313
+196
+18% +$14.7K ﹤0.01% 3998
2020
Q4 		$68K Buy
1,117
+216
+24% +$14.7K ﹤0.01% 3919
2020
Q3 		$110K Buy
901
+94
+12% +$10.7K ﹤0.01% 3777
2020
Q2 		$95K Sell
807
-1,169
-59% -$97.7K ﹤0.01% 3797
2020
Q1 		$105K Buy
1,976
+846
+75% +$60.4K ﹤0.01% 3723
2019
Q4 		$61K Buy
+1,130
New +$106K ﹤0.01% 3910

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Parametric Portfolio Associates's CYCN Position: Q3 2021 in Review

Parametric Portfolio Associates sold out of Cyclerion Therapeutics (CYCN) in Q3 2021, closing a stake of 630 shares — an estimated $49K sold.

Parametric Portfolio Associates first reported a position in CYCN in Q4 2019 and held it in 7 quarters. The position peaked at $110K in Q3 2020. 61 funds tracked by Wall St. Rank hold CYCN as of Q3 2021.

  • Parametric Portfolio Associates reported no remaining Cyclerion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 630 Cyclerion Therapeutics shares in Q3 2021, an estimated $49K.
  • Parametric Portfolio Associates first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 7 quarters.
  • Parametric Portfolio Associates's Cyclerion Therapeutics position peaked at $110K in Q3 2020.
  • 61 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2021.

Based on Parametric Portfolio Associates's 13F filing for Q3 2021, filed 15 Nov 2021.